Ten Bokkel Huinink 1998.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 120, ovarian cancer (stage II‐IV); concomitant treatment: chemotherapy
Interventions	drug = Epoetin beta dose = a: 150 IU/kg sc TIW, b: 300 IU/kg sc TIW hb‐target = 14‐15 g/dL planned ESA duration = during chemotherapy
Outcomes	Primary: transfusion; secondary: Hb, reticulocytes, Hct, safety
Notes	study number = 47852
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Low risk	central randomization